• Which Patients Are at Greatest Risk From Mushroom Poisoning?

Which Patients Are at Greatest Risk From Mushroom Poisoning?

Almost 20% of patients with liver damage from mushroom (Amanita) poisoning and peak levels of total bilirubin greater than 2 mg/dL require liver transplantation or die, researchers report in the May issue of Clinical Gastroenterology and Hepatology. The authors show that peak level of aspartate aminotransferase (AST) below 4000 IU/L identifies

Read more
  • What are the Effects of Prednisolone in Patients With Severe Alcoholic Liver Disease?

What are the Effects of Prednisolone in Patients With Severe Alcoholic Liver Disease?

Infections are frequent in patients with severe alcoholic liver disease, but are only independently associated with mortality when patients receive prednisolone, researchers report in the April issue of Gastroenterology. This could offset prednisolone’s therapeutic benefit. This study’s senior author, Mark Thursz, discusses the findings in a video abstract. As with

Read more
  • What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

In patients with chronic hepatitis B virus (HBV) infection who are negative for HBe antigen (HBeAg), monitoring levels of HB surface antigen (HBsAg) can predict disease progression, researchers report in the October issue of Clinical Gastroenterology and Hepatology. Most persons chronically infected with HBV clear HBeAg and enter an inactive carrier phase, characterized by low or undetectable

Read more
  • Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Three years of long-acting release octreotide (octreotide LAR) significantly reduced liver volume in patients with polycystic kidney and liver disease, researchers found in a placebo-controlled study. These reductions, reported in the July issue of Clinical Gastroenterology and Hepatology, were maintained for 2 years after treatment ended. Polycystic liver disease (PLD)

Read more
  • Can Nutritional Therapy Help Patients with Minimal Hepatic Encephalopathy?

Can Nutritional Therapy Help Patients with Minimal Hepatic Encephalopathy?

Nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy (MHE) not only improves their nutritional status, but increases cognitive function, health-related quality of life (HRQOL), and liver function and reduces hospitalization, researchers report in the March issue of Clinical Gastroenterology and Hepatology. HE is a spectrum of neuropsychiatric abnormalities that develops in

Read more
  • Almost 31,000 US Deaths Associated with Alcohol Use in 2014

Almost 31,000 US Deaths Associated with Alcohol Use in 2014

Americans are drinking themselves to death at a record-breaking rate, according a December 18 report from the Center for Disease Control and Prevention (CDC). In the Morbidity and Mortality Weekly Report, Rose A. Rudd et al reported that “30,700 Americans died from alcohol-induced causes, including alcohol poisoning and cirrhosis.” This

Read more

New Treatment Approved by FDA for Lysosomal Acid Lipase Deficiency

The Food and Drug Administration (FDA) approved a drug called sebelipase alfa (Kanuma) as the first-ever treatment for lysosomal acid lipase deficiency (LAL)—a rare inherited disorder. LAL deficiency causes a build-up of fats within the cells of various tissues that can lead to liver and cardiovascular diseases and other complications.

Read more
  • Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Sofosbuvir-based regimens, with or without daclatasvir, greatly improve the clinical status of patients who develop fibrosing cholestatis hepatitis (FCH) after liver transplantation for hepatitis C virus (HCV) infection, and most of the patients achieve a sustained virologic response (SVR), researchers report in the November issue of Clinical Gastroenterology and Hepatology. These results

Read more
  • Special Issue: Managing Patients With Liver Disease

Special Issue: Managing Patients With Liver Disease

A special issue of Clinical Gastroenterology and Hepatology is dedicated to the clinical management of hepatic disorders, including nonalcoholic fatty liver disease (NAFLD), viral hepatitis, autoimmune hepatitis, and primary sclerosing cholangitis (PSC). The issue comprises 14 review articles that aim to present clinicians with evidence-based guidance and expert opinions on management of patients with liver

Read more
  • What is the Best Treatment for Severe Alcoholic Hepatitis?

What is the Best Treatment for Severe Alcoholic Hepatitis?

Corticosteroids, alone or in combination with pentoxifylline or N-acetylcysteine (NAC), reduce short-term mortality in patients with severe alcoholic hepatitis, a meta-analysis shows in the October issue of Gastroenterology. However, there is no treatment to reduce medium-term mortality, the authors find. Severe alcoholic hepatitis is characterized by progressive inflammatory injury to hepatocytes and

Read more